Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification
The TMVR provided excellent outcomes for patients with degenerated bioprostheses despite high surgical risk, however, ViR and ViMAC were associated with higher rates of adverse events and mid-term mortality compared with ViV. Expand
Transcatheter Therapies for Treating Tricuspid Regurgitation.
- J. Rodés-Cabau, R. Hahn, +7 authors A. Vahanian
- Journal of the American College of Cardiology
- 19 April 2016
Currently available transcatheter treatment options for severe TR implanted at different levels are described: the junction between vena cavae and right atrium; the tricuspid annulus; or between TV leaflets, improving coaptation. Expand
Percutaneous Left-Ventricular Support With the Impella-2.5–Assist Device in Acute Cardiogenic Shock: Results of the Impella–EUROSHOCK-Registry
In patients with acute cardiogenic shock from acute myocardial infarction, Impella 2.5–treatment is feasible and results in a reduction of lactate levels, suggesting improved organ perfusion, however, 30-day mortality remains high in these patients. Expand
Axillary artery cannulation: routine use in ascending aorta and aortic arch replacement.
- J. Strauch, D. Spielvogel, +4 authors Randall B. Griepp
- The Annals of thoracic surgery
- 1 July 2004
The results suggest that axillary artery cannulation, successful in 95% of patients, may be the optimal technique for reducing perfusion-related morbidity and adverse outcome in operations for acute dissection, atherosclerotic, and degenerative aneurysmal disease. Expand
Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation
Transcatheter treatment of severe TR by caval valve implantation is feasible resulting in an immediate abolition of IVC regurgitation and mid-term clinical improvement, and in selected non-surgical patients, caval valves implantation may become a therapeutic option to treat venous regurgitations and improve associated non-cardiac diseases. Expand
Mild hypothermia protects the spinal cord from ischemic injury in a chronic porcine model.
- J. Strauch, A. Lauten, +5 authors Randall B. Griepp
- European journal of cardio-thoracic surgery…
- 1 May 2004
Observations indicate that mild hypothermia dramatically increases the tolerance of the spinal cord to ischemia in the pig, and therefore suggests that cooling to 32.0 degrees C should be encouraged during surgery which may compromise spinal cord blood supply. Expand
Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock: Matched-Pair IABP-SHOCK II Trial 30-Day Mortality Analysis
In this retrospective analysis of patients with AMI-CS, the use of an Impella device was not associated with lower 30-day mortality compared with matched patients from the IABP-SHOCK II trial treated with an IABp or medical therapy. Expand
Transcatheter aortic valve implantation in patients with low-flow, low-gradient aortic stenosis.
In high-risk patients with LG-AS, TAVI is associated with a significantly higher mortality at 30 days and at 1 year, however, long-term survivors benefit from TAVi with functional improvement and a significantly increased quality of life. Expand
The Occlutech Figulla PFO and ASD occluder: a new nitinol wire mesh device for closure of atrial septal defects.
- F. Krizanic, H. Sievert, +6 authors H. Figulla
- The Journal of invasive cardiology
- 1 April 2010
The novel Occlutech devices appear to be safe, feasible and effective for PFO and ASD closure, with a significant reduction of the meshwork and absence of left atrial central pin. Expand
Percutaneous bicaval valve implantation for transcatheter treatment of tricuspid regurgitation: clinical observations and 12-month follow-up.
- A. Lauten, T. Doenst, A. Hamadanchi, M. Franz, H. Figulla
- Circulation. Cardiovascular interventions
- 1 April 2014
The human application and 12-month follow-up after first bicaval implantation of self- expanding valves into the superior (SVC) and inferior (IVC) vena cava as interventional concept for severe tricuspid regurgitation is reported. Expand